Showing results (1331-1340 of 1,523) with videos related to

Sort By:
Pageof 153
Lung Cancer (Amsterdam, Netherlands)|September 13, 2025
Chinese expert consensus on perioperative management of patients with resectable anaplastic lymphoma kinase-fusion non-small cell lung cancerHai-Yan Tu, Chun Chen, Chang Chen, et al.
Future Oncology (London, England)|June 12, 2023
Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancerBenjamin J Solomon, Todd M Bauer, Tony S K Mok, et al.
Journal of Translational Medicine|July 10, 2026
The effects of probiotics duration and type on immunotherapy efficacy in non-small cell lung cancer with or without antibioticsWei-Chi Luo, Zi-Jian Huang, Shi-Qi Mei, et al.
Lung Cancer (Amsterdam, Netherlands)|October 20, 2012
Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancerJin-Ji Yang, Hua-Jun Chen, Hong-Hong Yan, et al.
Frontiers in Oncology|July 26, 2021
Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb StudiesAntonio Passaro, Filippo de Marinis, Hai-Yan Tu, et al.
Frontiers in Cellular Neuroscience|October 17, 2017
Wnt5a Promotes Cortical Neuron Survival by Inhibiting Cell-Cycle ActivationLi Zhou, Di Chen, Xu-Ming Huang, et al.
Lung Cancer (Amsterdam, Netherlands)|April 17, 2026
Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trialFabrice Barlesi, Jin Seok Ahn, Benjamin J Solomon, et al.
The New England Journal of Medicine|June 1, 2026
Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung CancerYi-Long Wu, Maximilian Hochmair, Yi Yang, et al.
Annals of Surgical Oncology|May 27, 2026
The Role of PD-L1 in Treatment Decision-Making for Perioperative EGFR-Mutated Lung Cancer and its Genomic AnalysisYi-Fan Qi, Zhen-Bin Qiu, Wei-Ye Huang, et al.
The Lancet. Oncology|July 11, 2015
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trialJean-Charles Soria, Yi-Long Wu, Kazuhiko Nakagawa, et al.
Pageof 153